UPDATED: Gilead picks up blockbuster FDA blood cancer approvals for idelalisib

John Carroll

said today that the FDA has approved its PI3k inhibitor for three types of B-cell cancers following its early Phase III success last fall on impressive leukemia data. EvaluatePharma analysts estimate this drug could earn $ 1.2 billion a year by 2020, making it one of the top therapies in late-stage development.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS